EXHIBIT B

Pending Claims

12. (Four Times Amended) A pharmaceutical composition comprising an N-acyl derivative of a D- or L-tryptophanyl-ester for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases having the following formula:



wherein X is $C(O)R_1$, and R_1 is a saturated C_1-C_{18} hydrocarbon residue and R_2 is a saturated or unsaturated C_2-C_{18} hydrocarbon residue, and a pharmaceutically acceptable carrier in combination with a second therapeutic compound.

16. (Amended) The pharmaceutical composition according to claim 12, wherein the N-acyl derivative is selected from the group consisting of N-acetyl-tryptophanoctyl-ester,
-acetyl-tryptophandodecyl-ester,
-acetyl-tryptophanstearyl-ester,
-acetyl-tryptophanpalmityl-ester, -acetyl-tryptophanoleyl-ester,
-dodecanoyl-tryptophanoctyl-ester,
-dodecanoyl-tryptophandodecyl-ester,
-dodecanoyl-tryptophanstearyl-ester,

-dodecanoyl-tryptophanpalmityl-ester,

-dodecanoyl-tryptophanoleyl-ester,

-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester,

N-octoyl-tryptophanethyl-ester,

-dodecanoyl-tryptophanethyl-ester, N-

stearoyl-tryptophanethyl-ester and

N-palmitoyl-tryptophanethyl-ester.

17. (Twice Amended) The pharmaceutical composition according to claim 12, wherein the N-acyl derivative is selected from the group consisting of N-dodecanoyl-tryptophanethyl-ester.

18. (Twice Amended) A pharmaceutical composition comprising an N-acyl derivative of a D- or L-tryptophanyl-ester, wherein the N-acyl derivative has the following formula:



wherein X is $C(O)R_1$, and R_1 is a saturated C_1-C_{18} or unsaturated C_2-C_7 hydrocarbon residue and R_2 is a saturated or unsaturated C_9-C_{18} hydrocarbon residue, and a pharmaceutically acceptable carrier in combination with a second therapeutic compound.

19. (Amended) The pharmaceutical composition according to claim 18, wherein the N-acyl derivative is selected from the group consisting of N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester,

N-acetyl-tryptophanpalmityl-ester,

N-acetyl-tryptophanoleyl-ester,

N-dodecanoyl-tryptophanoctyl-ester,

N-dodecanoyl-tryptophandodecyl-ester,

N-dodecanoyl-tryptophanstearyl-ester,

N-dodecanoyl-tryptophanpalmityl-ester,

N-dodecanoyl-tryptophanoleyl-ester,

N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester,

N-dodecanoyl-tryptophanethyl-ester,

N-stearoyl-tryptophanethyl-ester and

N-palmitoyl-tryptophanethyl-ester.

20. (Amended) The pharmaceutical composition according to claim 18, wherein the N-acyl derivative is N-dodecanoyl-tryptophanethyl-ester.

22. (Amended) The composition according to claim 12 or 18, wherein the second therapeutic compound is for treating a degenerative disease or cancer.

23. (Twice Amended) The pharmaceutical composition according to claim 12 or 18, wherein the second therapeutic compound is selected from the group consisting of ciliary neurotropic factor (CNTF), aniracetam, buflomedil, choline, co-dergocrine, cyclandelate, desferrioxamine, eptastigmine, fampridine, galantamine, isoxusuprine, linopiridine, metriphonate, naftidrofuryl, nicergoline, nicotine, nimodipine, oxiracetam, physostigmine, pilocarpine, piracetam, pramiracetam, propentofylline, pyritinol, RS-86, selegiline, suronacrine,

tacrine, velnacrine, somatomedines, protirelin, and an immunoglobulin.

24. (Amended) The composition according to claim 18, wherein the degenerative disease is selected from the group consisting of Alzheimers' disease, Parkinson's disease, apoplectic fit and amyotrophic lateral sclerosis.

25. (Amended) The composition according to claim 18, wherein the degenerative disease is Alzheimers' disease.

26. (Amended) The composition according to claim 18, wherein the degenerative disease is Parkinson's disease.

27. (Amended) The composition according to claim 18, wherein the degenerative disease is apoplectic fit.

28. (Amended) The composition according to claim 18, wherein the degenerative disease is amyotrophic lateral sclerosis.

29. A pharmaceutical composition comprising a D- or L-tryptophanyl-ester selected from the group consisting of tryptophanoctyl-ester, tryptophanstearyl-ester, tryptophanpalmityl-ester and tryptophanoleyl-ester.